OPCH Stock Analysis — Option Care Health
Sector: Healthcare
AI Verdict
OPCH trades at 10.4x next year's earnings with 49.3% EPS growth expected — that's cheap for the growth you're getting, and the scale-driven moat makes those expectations credible if execution holds.
Competitive Moat
Option Care Health operates one of the largest independent providers of home and alternate site infusion services in the U.S., leveraging a national pharmacy network and payer relationships that make it difficult for smaller rivals to match scale or reimbursement access. Its integrated care model and established referral channels with hospitals and physicians create high switching costs for both patients and providers.
Summary
OPCH stands out for its 49.3% expected EPS growth next year, paired with a forward P/E of just 10.4x.
Where It Stands
The stock delivered 9.3% revenue growth last year and trades at 10.4x forward earnings, well below the healthcare sector median of 22x, with a trailing PEG of 0.32 signaling growth is more than priced in.
Key Metrics
- Trailing P/E: 15.5x
- Forward P/E: 10.4x
- PEG Ratio: 0.32
- Earnings Growth: +0.5%
- Revenue Growth: +0.1%
- 52-Week High: $36.80
- 52-Week Low: $18.01
Analyst Consensus
16 Buy · 2 Hold · 0 Sell (18 analysts)
Bull Case
With analysts forecasting 49.3% EPS growth and a forward P/E of 10.4x, OPCH offers rapid earnings expansion at a valuation less than half the sector average.
Bear Case
If the forward P/E rises to the sector median of 22x without a matching jump in earnings, the stock could double in price and become expensive for its growth profile.
Catalyst to Watch
Watch for quarterly earnings updates — any miss on the 49.3% EPS growth forecast would likely trigger a sharp rerating.